The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2017 | Can nivolimumab aid in preventing gastrointestinal cancer progression?
Ronan Joseph Kelly, MBA, MBBCh, MD, from the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the current proceedings of the CheckMate 577 trial (NCT02743494), a large ongoing Phase III study investigating the effectiveness of nivolumab in treating gastroesophageal or esophageal cancer, specifically in post-surgery patients who do not achieve a complete pathological response with standard treatment. He states that the study will take 1-2 years to achieve completion and hopes that the results will be positive, which will aid in preventing progression of cancer. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.
